Larimar Therapeutics, Inc. (LRMR) Misses Q4 EPS by 14c

Larimar Therapeutics, Inc. (NASDAQ: LRMR) reported Q4 EPS of ($0.45), $0.14 worse than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Larimar Therapeutics, Inc. (LRMR) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• AiRWA receives Nasdaq deficiency notice over late 10-K filing
• Lobe Sciences upsizes private placement to $2.16M